How Did Wellnex Life Limited (ASX:WNX) Cut Its FY26 Loss and Plan the Pain Away Divestment?

Aditi Sarkar

29 October 2026 05:09 PM AEDT

How Did Wellnex Life Limited (ASX:WNX) Cut Its FY26 Loss and Plan the Pain Away Divestment?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

On 29 October 2026, Wellnex Life Limited (ASX:WNX) was quoted at AUD 0.066, with the daily change shown as unchanged. This article covers fy26 revenue and margins, net loss and ebitda and the company’s wider disclosures.
Wellnex FY26 revenue increased 5.1% to AUD 24.8 million and its net loss narrowed to AUD 4.5 million.
A proposed sale of Pain Away included AUD 19.8 million of upfront consideration and a possible earn-out.

Wellnex Life Limited (ASX:WNX) reported company-specific developments spanning its latest results and operating activities. On 29 October 2026, Wellnex Life Limited (ASX:WNX) was quoted at AUD 0.066, with the daily change shown as unchanged. Wellnex FY26 revenue increased 5.1% to AUD 24.8 million and its net loss narrowed to AUD 4.5 million. A proposed sale of Pain Away included AUD 19.8 million of upfront consideration and a possible earn-out. The disclosures also address business turnaround and costs and retained operations and balance sheet.

FY26 Revenue and Margins

Wellnex reported audited revenue of AUD 24.8 million for the year ended 30 June 2026, an increase of 5.1% from AUD 23.6 million in FY25. Group gross margin increased to 30.2%, compared with 29.0% in the previous financial year. The company attributed the operating movement to changes in business processes, improved spending discipline and the broader turnaround undertaken during FY26. Those measures were reported alongside financial results, rather than a claim that the company had returned to statutory profitability.

Net Loss and EBITDA

The statutory net loss narrowed to approximately AUD 4.5 million from AUD 15.6 million in FY25, representing a reduction of about 70.8%. The company also reported that its EBITDA loss decreased to AUD 1.7 million from around AUD 12.1 million. These measures reflect different accounting definitions: the net loss is the bottom-line statutory outcome, while EBITDA is a separate measure before interest, tax, depreciation and amortisation. The FY26 results therefore showed a smaller loss alongside a higher revenue base.

Business Turnaround and Costs

During FY26, Wellnex commenced a strategic turnaround program directed at reducing overheads and simplifying the operating model. Management targeted more than AUD 1 million of annualised operating savings through corporate cost controls and capital management. The reported results cover the period during which the turnaround commenced, while the savings target was an intended annualised amount. Management also discussed positioning the company around retained consumer healthcare and contract manufacturing activities once the proposed divestment process was completed.

Proposed Pain Away Disposal

After year-end, Wellnex entered a binding agreement to divest its Pain Away business for AUD 19.8 million of upfront consideration, with an additional contingent earn-out of up to AUD 1.5 million. The transaction was subject to shareholder approval at an extraordinary general meeting scheduled for 8 September 2026, as stated in the August announcement. The reported proceeds were therefore proposed transaction terms, not cash confirmed as received in that release. Management outlined debt reduction and additional balance-sheet flexibility as intended uses of sale proceeds.

Retained Operations and Balance Sheet

The proposed transaction was part of a broader change in the group’s business mix. Wellnex described plans to focus on its retained consumer healthcare and contract manufacturing operations, while reducing debt following completion of the sale. The audited FY26 result preceded the proposed disposal and should not be read as a post-transaction financial statement. At the disclosure date, the proposed deal remained subject to the stated approval and completion conditions, and the company’s future position depended on those steps.

Key Insights

Overall, Wellnex Life Limited reported wellnex FY26 revenue increased 5.1% to AUD 24.8 million and its net loss narrowed to AUD 4.5 million. a proposed sale of Pain Away included AUD 19.8 million of upfront consideration and a possible earn-out. The announcement also addresses business turnaround and costs, proposed pain away disposal and retained operations and balance sheet. These are company-reported results and planned activities for their stated periods; announced targets, proposed transactions and pending approvals remain distinct from completed outcomes.

FAQs

Q: What was Wellnex’s FY26 revenue?

A: AUD 24.8 million, up 5.1%.

Q: What was the FY26 net loss?

A: Approximately AUD 4.5 million.

Q: What EBITDA loss was reported?

A: Approximately AUD 1.7 million.

Q: What was the proposed upfront Pain Away sale amount?

A: AUD 19.8 million.

Q: Was an earn-out included?

A: Yes, contingent consideration of up to AUD 1.5 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.